Feeds:
Posts
Comments

Archive for the ‘Scientific & Biotech Conferences: Press Coverage’ Category


Is It Time for the Virtual Scientific Conference?: Coronavirus, Travel Restrictions, Conferences Cancelled

Curator: Stephen J. Williams, PhD.

UPDATED 3/12/2020

To many of us scientists, presenting and attending scientific meetings, especially international scientific conferences, are a crucial tool for disseminating and learning new trends and cutting edge findings occurring in our respective fields.  Large international meetings, like cancer focused meetings like AACR (held in the spring time), AAAS and ASCO not only highlight the past years great discoveries but are usually the first place where breakthroughs are made known to the scientific/medical community as well as the public.  In addition these conferences allow for scientists to learn some of the newest technologies crucial for their work in vendor exhibitions.

During the coronavirus pandemic, multiple cancellations of business travel, conferences, and even university based study abroad programs are being cancelled and these cancellations are now hitting the 2020 Spring and potentially summer scientific/medical conferences.  Indeed one such conference hosted by Amgen in Massachusetts was determined as an event where some attendees tested positive for the virus, and as such, now other attendees are being asked to self quarantine.

Today I received two emails on conference cancellations, one from Experimental Biology in California and another from The Cancer Letter, highlighting other conferences, including National Cancer Coalition Network (NCCN) meetings which had been canceled.

 

Experimental Biology - San Diego 2020 - April 4-7

Dear Stephen,

After thoughtful deliberations, the leaders of the Experimental Biology host societies have made the difficult but necessary decision to cancel Experimental Biology (EB) 2020 set to take place April 4–7 in San Diego, California. We know how much EB means to everyone, and we did not make this decision in haste. The health and safety of our members, attendees, their students, our staff, partners and our communities are our top priority.

As we have previously communicated via email, on experimentalbiology.org and elsewhere, EB leadership has been closely monitoring the spread of COVID-19 (coronavirus disease). Based on the latest guidance from public health officials, the travel bans implemented by different institutions and the state of emergency declared in California less than 48 hours ago, it became clear to us that canceling was the right course of action.

We thank you and the entire EB community for understanding the extreme difficulty of this decision and for your commitment to the success of this conference – from the thousands of attendees to the presenters, exhibitors and sponsors who shared their time, expertise, collaboration and leadership. We deeply appreciate your contributions to this community.

What Happens Next?

Everyone who has registered to attend the meeting will receive a full registration refund within the next 45 days. Once your registration cancellation is processed, you will receive confirmation in a separate email. You do not need to contact anyone at EB or your host society to initiate the process. Despite the cancellation of the meeting, we are pleased to tell you that we will publish abstracts in the April 2020 issue of The FASEB Journal as originally planned. Please remember to cancel any personal arrangements you’ve made, such as travel and housing reservations. 

We ask for patience as we evaluate our next steps, and we will alert you as additional information becomes available please see our FAQs for details.

And in The Cancer Letter

Coronavirus vs. oncology: Meeting cancellations, travel restrictions, fears about drug supply chain

By Alexandria Carolan

NOTE: An earlier version of this story was published March 4 on the web and was updated March 6 to include information about restricted travel for employees of cancer centers, meeting cancellations, potential disruptions to the drug supply chain, and funds allocated by U.S. Congress for combating the coronavirus.

Further updates will be posted as the story develops.

Forecasts of the inevitable spread of coronavirus can be difficult to ignore, especially at a time when many of us are making travel plans for this spring’s big cancer meetings.

The decision was made all the more difficult earlier this week, as cancer centers and at least one biotechnology company—Amgen—implemented travel bans that are expected to last through the end of March and beyond. The Cancer Letter was able to confirm such travel bans at Fred Hutchinson Cancer Research Center, MD Anderson Cancer Center, and Dana-Farber Cancer Institute.

Meetings are getting cancelled in all fields, including oncology:

The National Comprehensive Cancer Network March 5 postponed its 2020 annual conference of about 1,500 attendees March 19-22 in Orlando, citing precautions against coronavirus.

“The health and safety of our attendees and the patients they take care of is our number one concern,” said Robert W. Carlson, chief executive officer of NCCN. “This was an incredibly difficult and disappointing decision to have to make. However, our conference attendees work to save the lives of immunocompromised people every day. Some of them are cancer survivors themselves, particularly at our patient advocacy pavilion. It’s our responsibility, in an abundance of caution, to safeguard them from any potential exposure to COVID-19.”

UPDATED 3/12/2020

And today the AACR canceled its yearly 2020 Meeting (https://www.aacr.org/meeting/aacr-annual-meeting-2020/coronavirus-information/)

The American Association for Cancer Research (AACR) Board of Directors has made the difficult decision, after careful consideration and comprehensive evaluation of currently available information related to the novel coronavirus (COVID-19) outbreak, to terminate the AACR Annual Meeting 2020, originally scheduled for April 24-29 in San Diego, California. A rescheduled meeting is being planned for later this year.

The AACR has been closely monitoring the rapidly increasing domestic and worldwide developments during the last several weeks related to COVID-19. This evidence-based decision was made after a thorough review and discussion of all factors impacting the Annual Meeting, including the U.S. government’s enforcement of restrictions on international travelers to enter the U.S.; the imposition of travel restrictions issued by U.S. government agencies, cancer centers, academic institutions, and pharmaceutical and biotech companies; and the counsel of infectious disease experts. It is clear that all of these elements significantly affect the ability of delegates, speakers, presenters of proffered papers, and exhibitors to participate fully in the Annual Meeting.

The health, safety, and security of all Annual Meeting attendees and the patients and communities they serve are the AACR’s highest priorities. While we believe that the decision to postpone the meeting is absolutely the correct one to safeguard our meeting participants from further potential exposure to the coronavirus, we also understand that this is a disappointing one for our stakeholders. There had been a great deal of excitement about the meeting, which was expected to be the largest ever AACR Annual Meeting, with more than 7,400 proffered papers, a projected total of 24,000 delegates from 80 countries and more than 500 exhibitors. We recognize that the presentation of new data, exchange of information, and opportunities for collaboration offered by the AACR Annual Meeting are highly valued by the entire cancer research community, and we are investigating options for rescheduling the Annual Meeting in the near future.

We thank all of our stakeholders for their patience and support at this time. Additional information regarding hotel reservation cancellations, registration refunds, and meeting logistics is available on the FAQ page on the AACR website. We will announce the dates and location of the rescheduled AACR Annual Meeting 2020 as soon as they are confirmed. Our heartfelt sympathies go out to everyone impacted by this global health crisis.

However,  according to both Dr. Fauci and Dr. Scott Gottlieb (former FDA director)  the outbreak may revisit the US and the world in the fall (see https://www.cnbc.com/2020/03/04/were-losing-valuable-time-ex-fda-chief-says-of-coronavirus-spread.html)  therefore these meetings may be cancelled for the whole year.

Is It Time For the Virtual (Real-Time) Conference?

Readers of this Online Access Journal are familiar with our ongoing commitment to open science and believe that forming networks of scientific experts in various fields using a social strategy is pertinent to enhancing the speed, reproducibility and novelty of important future scientific/medical discoveries.  Some of these ideas are highlighted in the following articles found on this site:

Scientific Curation Fostering Expert Networks and Open Innovation: Lessons from Clive Thompson and others

Old Industrial Revolution Paradigm of Education Needs to End: How Scientific Curation Can Transform Education

Twitter is Becoming a Powerful Tool in Science and Medicine

e-Scientific Publishing: The Competitive Advantage of a Powerhouse for Curation of Scientific Findings and Methodology Development for e-Scientific Publishing – LPBI Group, A Case in Point

Reconstructed Science Communication for Open Access Online Scientific Curation

In addition, we understand the importance of communicating the latest scientific/medical discoveries in an open and rapid format, accessible over the social media platforms.  To this effect we have developed a methodology for real time conference coverage

see  Press and Conference Coverage

at  https://pharmaceuticalintelligence.com/press-coverage/

AND

The Process of Real Time Coverage using Social Media

at https://pharmaceuticalintelligence.com/press-coverage/part-one-the-process-of-real-time-coverage-using-social-media/

Using these strategies we are able to communicate, in real time, analysis of conference coverage for a multitude of conferences.

Has technology and social media platforms now have enabled our ability to rapidly communicate, in a more open access platform, seminal discoveries and are scientists today amenable to virtual type of meetings including displaying abstracts using a real-time online platform?

Some of the Twitter analytics we have curated from such meetings show that conference attendees are rapidly adopting such social platforms to communicate with their peers and colleagues meeting notes.

Statistical Analysis of Tweet Feeds from the 14th ANNUAL BIOTECH IN EUROPE FORUM For Global Partnering & Investment 9/30 – 10/1/2014 • Congress Center Basel – SACHS Associates, London

Word Associations of Twitter Discussions for 10th Annual Personalized Medicine Conference at the Harvard Medical School, November 12-13, 2014

Comparative Analysis of the Level of Engagement for Four Twitter Accounts: @KDNuggets (Big Data) @GilPress @Forbes @pharma_BI @AVIVA1950

Twitter Analytics on the Inside 3DPrinting Conference #I3DPConf

 

Other Twitter analyses of Conferences Covered by LPBI in Real Time have produced a similar conclusion: That conference attendees are very engaged over social media networks to discuss, share, and gain new insights into material presented at these conferences, especially international conferences.

And although attracting international conferences is lucrative to many cities, the loss in revenue to organizations, as well as the loss of intellectual capital is indeed equally as great.  

Maybe there is room for such type of conferences in the future, and attending by a vast more audience than currently capable. And perhaps the #openscience movement like @MozillaScience can collaborate with hackathons to produce the platforms for such an online movement of scientific conferences as a Plan B.

Other articles on Real Time Conference Coverage in the Online Open Access Journal Include:

Innovations in electronic Scientific Publishing (eSP): Case Studies in Marketing eContent, Curation Methodology, Categories of Research Functions, Interdisciplinary conceptual innovations by Cross Section of Categories, Exposure to Frontiers of Science by Real Time Press coverage of Scientific Conferences

Real Time Coverage and eProceedings of Presentations on 11/16 – 11/17, 2016, The 12th Annual Personalized Medicine Conference, HARVARD MEDICAL SCHOOL, Joseph B. Martin Conference Center, 77 Avenue Louis Pasteur, Boston

Tweets by @pharma_BI and by @AVIVA1950: Real Time Coverage and eProceedings of The 11th Annual Personalized Medicine Conference, November 18-19, 2015, Harvard Medical School

REAL TIME Cancer Conference Coverage: A Novel Methodology for Authentic Reporting on Presentations and Discussions launched via Twitter.com @ The 2nd ANNUAL Sachs Cancer Bio Partnering & Investment Forum in Drug Development, 19th March 2014 • New York Academy of Sciences • USA

Search Results for ‘Real Time Conference’

Read Full Post »


In Data Science, A Pioneer Practitioner’s Portfolio of Algorithm-based Decision Support Systems for Operations Management in Several Industrial Verticals: Analytics Designer, Aviva Lev-Ari, PhD, RN

An overview of Data Science as a discipline is presented in

Data Science & Analytics: What do Data Scientists Do in 2020 and a Pioneer Practitioner’s Portfolio of Algorithm-based Decision Support Systems for Operations Management in Several Industrial Verticals

 

On this landscape about IT, The Internet, Analytics, Statistics, Big Data, Data Science and Artificial Intelligence, I am to tell stories on my own pioneering work in data science, Algorithm-based decision support systems design for different organizations in several sectors of the US economy:

Images on 12/7/2019

  • Startups:
  1. TimeØ Group – The leader in Digital Marketplaces Design
  2. Concept Five Technologies, Inc. – Commercialization of DoD funded technologies
  3. MDSS, Inc. – SAAS in Analytical Services
  4. LPBI Group – Pharmaceutical & Media
  • Top Tier Management Consulting: SRI International, Monitor Group;
  • OEM: Amdahl Corporation;
  • Top 6th System Integrator: Perot System Corporation;
  • FFRDC: MITRE Corporation.
  • Publishing industry: was Director of Research at McGraw-Hill/CTB.
  • Northeastern University, Researcher on Cardiovascular Pharmacotherapy at Bouve College of Health Sciences (Independent research guided by Professor of Pharmacology)

Type of institutions:

  • For-Profit corporations: Amdahl Corp, PSC, McGraw-Hill
  • For-Profit Top Tier Consulting: Monitor Company, Now Deloitte
  • Not-for-Profit Top Tier Consulting: SRI International
  • FFRDC: MITRE
  • Pharmaceutical & Media Start up in eScientific Publishing: LPBI Group:
  1. Developers of Curation methodology for e-Articles [N = 5,700],
  2. Developers of electronic Table of Contents for e-Books in Medicine [N = 16, https://lnkd.in/ekWGNqA] and
  3. Developers of Methodologies for real time press coverage and production of e-Proceedings of Biotech Conferences [N = 70].

 

Autobiographical Annotations: Tribute to My Professors

 

Pioneering implementations of analytics to business decision making: contributions to domain knowledge conceptualization, research design, methodology development, data modeling and statistical data analysis: Aviva Lev-Ari, UCB, PhD’83; HUJI MA’76

https://pharmaceuticalintelligence.com/2018/05/28/pioneering-implementations-of-analytics-to-business-decision-making-contributions-to-domain-knowledge-conceptualization-research-design-methodology-development-data-modeling-and-statistical-data-a/

Recollections of Years at UC, Berkeley, Part 1 and Part 2

  • Recollections: Part 1 – My days at Berkeley, 9/1978 – 12/1983 – About my doctoral advisor, Allan Pred, other professors and other peers

https://pharmaceuticalintelligence.com/2018/03/15/recollections-my-days-at-berkeley-9-1978-12-1983-about-my-doctoral-advisor-allan-pred-other-professors-and-other-peer/

  • Recollections: Part 2 – “While Rolling” is preceded by “While Enrolling” Autobiographical Alumna Recollections of Berkeley – Aviva Lev-Ari, PhD’83

https://pharmaceuticalintelligence.com/2018/05/24/recollections-part-2-while-rolling-is-preceded-by-while-enrolling-autobiographical-alumna-recollections-of-berkeley-aviva-lev-ari-phd83/

Accomplishments

The Digital Age Gave Rise to New Definitions – New Benchmarks were born on the World Wide Web for the Intangible Asset of Firm’s Reputation: Pay a Premium for buying e-Reputation

For @AVIVA1950, Founder, LPBI Group @pharma_BI: Twitter Analytics [Engagement Rate, Link Clicks, Retweets, Likes, Replies] & Tweet Highlights [Tweets, Impressions, Profile Visits, Mentions, New Followers] https://analytics.twitter.com/user/AVIVA1950/tweets

Thriving at the Survival Calls during Careers in the Digital Age – An AGE like no Other, also known as, DIGITAL

Professional Self Re-Invention: From Academia to Industry – Opportunities for PhDs in the Business Sector of the Economy

Reflections on a Four-phase Career: Aviva Lev-Ari, PhD, RNMarch 2018

Was prepared for publication in American Friends of the Hebrew University (AFHU), May 2018 Newsletter, Hebrew University’s HUJI Alumni Spotlight Section.

Aviva Lev-Ari’s profile was up on 5/3/2018 on AFHU website under the Alumni Spotlight at https://www.afhu.org/

On 5/11/2018, Excerpts were Published in AFHU e-news.

https://us10.campaign-archive.com/?u=5c25136c60d4dfc4d3bb36eee&id=757c5c3aae&e=d09d2b8d72

https://www.afhu.org/2018/05/03/aviva-lev-ari/

 

Read Full Post »


DISCOVER BRIGHAM | NOVEMBER 7, 2019, 10AM – 6PM

#DISCOVERBRIGHAM

@pharma_BI

@AVIVA1950

 Aviva Lev-Ari, PhD, RN will be attending and will cover presentations in real time

ABOUT BRIGHAM RESEARCH

Discover Brigham is hosted by the Brigham Research Institute (BRI), under the umbrella of Brigham Health. Launched in 2005, the BRI’s mission is to accelerate discoveries that improve human health by bridging the gaps between science, communication and funding. The BRI’s resources help to foster groundbreaking interdepartmental and interdisciplinary research. They provide a voice for the research community and raise the profile of Brigham Research.

Speakers

http://www.discoverbrigham.org/speakers/

 

AGENDA

http://www.discoverbrigham.org/agenda/

ASK A QUESTION WITH SLI.DO!

DO YOU WANT TO SUBMIT A QUESTION TO A SPEAKER OF A SESSION? YOU CAN DO IT THROUGH SLI.DO!

2. ENTER THE EVENT CODE: DB19. THEN HIT JOIN!
3. PICK THE SESSION YOU WANT TO ASK A QUESTION. THEN ASK YOUR QUESTION!
4. YOUR QUESTION WILL BE REVIEWED AND MAY BE FORWARDED TO THE CHAIR TO ASK THE SPEAKER(S).

IT WORKS ON ANY DEVICE, YOU DO NOT NEED TO INSTALL ANYTHING!

 

Registration will open at 9:00 AM and will be located throughout the hospital including

  • Schlager Atrium (formerly known as Cabot Atrium, 45 Francis Street Lobby),
  • Schuster Lobby (75 Francis Street Entrance),
  • Shapiro Cardiovascular Center (70 Francis Street Entrance), and the
  • Hale Building for Transformative Medicine (HBTM) 1st Floor (60 Fenwood Road).

 

Click here for directions to these locations.  

NAVIGATING THE BRIGHAM IS EASIER THAN EVER

Need directions to a clinic, conference room, public space, or help assisting someone who looks lost?

Try our browser-based wayfinding tool and mobile app, BWH Maps,
which provides real-time location tracking and directions in the hospital.

Look for BWH Maps on the Apple App Store and Google Play Store,
or visit maps.brighamandwomens.org.

REGISTRATION LOCATIONS

Please visit one of the registration desks listed below to check-in, receive your badge, and collect any necessary materials. Registration will begin starting at 9:00 AM at each of the locations below.

 

Click on each location below for directions. 

  • SCHLAGER ATRIUM, FORMERLY KNOWN AS CABOT ATRIUM (45 FRANCIS ST. LOBBY)
  • SCHUSTER LOBBY (75 FRANCIS ST. LOBBY)
  • CARL J. AND RUTH SHAPIRO
    CARDIOVASCULAR CENTER
  • HALE BUILDING FOR
    TRANSFORMATIVE MEDICINE

SESSION LOCATIONS

Below you will find directions to each of the session locations.

MARSHALL A. WOLF CONFERENCE ROOM

HALE BUILDING FOR TRANSFORMATIVE MEDICINE

SESSION ROOM

FROM 60 FENWOOD ROAD:
Enter at 60 Fenwood Rd lobby entrance.

STAIRS:
Take the lobby staircase to the 2nd floor. Walk past the balcony overlooking the atrium and take the stairs on the left (Stair 2) to the 3rd floor. Once on the 3rd floor, exit the stairwell and take a right. The room is to your right through the double glass door, straight ahead.

ELEVATOR:
Take S Elevator to 3rd floor. Take a right out of the elevator. The room is past the stairwell, on your right through the double glass doors.

HALE VTC 02006B CONFERENCE ROOM

HALE BUILDING FOR TRANSFORMATIVE MEDICINE

OVERFLOW ROOM FOR MARSHALL A. WOLF CONFERENCE ROOM

FROM 60 FENWOOD ROAD:
Enter at 60 Fenwood Rd lobby entrance.

STAIRS:
Take the lobby staircase to the 2nd floor. The conference room will be on your right near the display monitor.

ELEVATOR:
Enter at 60 Fenwood Rd main entrance and take the S Elevator to the 2nd floor. Once you exit the elevator, take a right and walk past the balcony overlooking the atrium and the conference room will be straight ahead near the display monitor.

ZINNER BREAKOUT ROOM

CARL J. AND RUTH SHAPIRO CARDIOVASCULAR CENTER

SESSION ROOM

FROM 70 FRANCIS STREET:
The Zinner Breakout Room is located in the Carl J. and Ruth Shapiro Cardiovascular Center at 70 Francis Street, Boston, MA. Upon entering the building at the street level, walk straight towards the escalators in the rear of the building. The Zinner Conference Center is located on your right; the Breakout room is through the large doors on the left.

ZINNER BOARDROOM

CARL J. AND RUTH SHAPIRO CARDIOVASCULAR CENTER

OVERFLOW ROOM FOR ZINNER BREAKOUT ROOM

FROM 70 FRANCIS STREET:
The Zinner Boardroom is located in the Carl J. and Ruth Shapiro Cardiovascular Center at 70 Francis Street, Boston, MA. Upon entering the building at the street level, walk straight towards the escalator, keeping to the left side of the building. The Conference Center is located on your right; the Boardroom is through the large doors on the back wall.

BORNSTEIN FAMILY AMPHITHEATER

MAIN PIKE, 45 FRANCIS STREET LOBBY

SESSION ROOM

FROM 45 FRANCIS STREET:
Coming from 45 Francis Street lobby, walk towards the Main Pike (2nd floor hallway). Then take left on the Main Pike, 2nd door on right.

AGENDA

10:00 AM – 11:00 AM

Opening remarks

Elizabeth G. Nabel, MD, President Brigham Health, Prof. Medicine @HarvardMed

  • 8th event since 2012
  • show casing amazing research
  • Open to the Public: Patients, Families to educate
  • 90 Posters
  • Health equity perspective as DNA of the Brigham
  • Learn a new idea, meet someone new, create a new idea

Keynote Introduction

David Bates, MD @DBatesSafety

KEYNOTE

KYU RHEE, MD, MPP, VICE PRESIDENT & CHIEF HEALTH OFFICER, IBM CORPORATION & IBM WATSON HEALTH

MAIN PIKE, 45 FRANCIS STREET LOBBY
  • Partnership BWH & IBM WATSON
  • Big data of claims from providers to payers
  • Waiting rookms in Healthcare delivery
  • Government: ACA
  • AI Spring is here, no more Winter for AI
  • Health disparities, salaries, sexual orientation – improving health of populations
  • Science & Security
  • Red Hat – data security – big data statoscope
  • Healthcare Culture & Technology Culture: IBM & Amazon hire healthcare professionals
  • Cost: Burnout, managing population health,
  • Reduce physicians burnout
  • Culture Tech – Competition by IBM’s Project Debater

11:15 AM – 12:50 PM

1:00 – 1:50 PM

FROM 70 FRANCIS STREET:
The Zinner Breakout Room is located in the Carl J. and Ruth Shapiro Cardiovascular Center at 70 Francis Street, Boston, MA. Upon entering the building at the street level, walk straight towards the escalators in the rear of the building. The Zinner Conference Center is located on your right; the Breakout room is through the large doors on the left.

Aaron Goldman
HaeLin Jang
Greog K. Gerber
  • Microbiome – Bacteria and Fungus therapies – computational tools for applications on microbiome
  • Diagnostics
  • Microbiome in early childhood
  • temporal variability during adulthood
  • host disease bacteriptherapeutics: C-Diff
  • Bugs as drugs
  • Gnotobiotic mice model for c-Diff in mice
  • MDSINE – Microbial dynamin model interaction model
  • cancer microbiome: Bacteria causing cancer, cancer changing the bacteria environment

 

Jeff Karp BENG PhD @MrJeffKarp

  • tissue based patch to seal open foramane ovale. Project remained in Academic settings however
  • GLUE component was commercialized
  • bioinspiration from living organs in Nature, slugs
  1. Viscose secretions
  2. Hydrophobic secretions and snails and sand castle worms

1:00 – 1:50 PM

Lina Matta, PharmD
Joji Suzuki, MD
Lisa WIchmann
Kevin Elias, MD
Daiva Braunfelds,MBA HPH
Elizabeth Cullen, MS

2:00 – 2:50 PM

3:00 – 3:50 PM

David Levin
Christopher baugh
Kathryn Britton
Joanne Feinberg Goldstein
Amrita Shahani
If patient meets criteria for Home Hospital : all services are sent home.
2016 – Pilot randomized controlled trial
2017-2018 – Repeat of Pilot on larger population
2018 – High-volume single arm innovation services
2019 – studies within home hospital wtth sensors at home
2020 – continue
Operation and Research lead to innovations

Anna Krichevsky, PhD HMS Initiative for RNA Medicine

  • paradox of organismal complexity and # protein encoding genes
  • Human genome, 70% Transcriptome Non-coding RNA only 2% encode proteins
  • Non-coding RNA small, long, multifunctional
  • biogenesis of offending RNAs can be drugged
  • RNA novel therapies: RNA as a Drug,
  • Indications: Brain Tumors and AD: MicroRNA (miRNA)the smallest Glioblastoma – only 4 drugs FDA approved in 25 years miRNA – 10b inhibition kills gliomacells miR-132 most neuroprotective RNA
  • Cardiovascular

Paul Anderson, MD, PhD

  • ALS and FTD – Fronto Temporal Dimensia
  • Riluzone 1970 – anti Anti-glutamateric
  • Edarabone 2017 drugs approved – anti-oxidative
  • Andogenesis role in Motor protection from Stress Cytoplasmatic tRNA – ANdiogenin (ANG) production
  • 20 amino acids
  • 5″-tiRNAs assemble G-quadruples – G4
  • point mutationin ANG (mANG) reduce its RNanase
  • G4-containing DNA analogs of 5″-tiRNA (Ala)

Marc Feinberg, MD

  • Cardiovascular: CAD, Insulin resistence – Vascular inflammation
  • Impaired angiogenesis: post MI repair CHF
  • MiRNA therapeutics for Atherosclerosis – miR-181b: Aortic ECs Athero (mice) CAD (Human)
  • miRNA _ Liposomes injected in the vessel wall – reduction of inflammation in vessel – microRNA Group
  • monocyte – How can we increase or amintain mir-181b expression in endothelial cells?
  • LncRNA Therapeutics for vascular Senescence and Atherosclerosis – no effect on leucocyte accumulation no difference in inflammation
  • DNA-dependent protein kinase (DNA-PK)
  • Does Loss SNHG12 triggers vascular senescence in the vessel wall

 

Clemens Scherzer, MD

  • The Protein RNA Brain
  • Dopamin p
  • BRAINCODE: 64% RNA: mRNA, ncRNA,
  • cell-type-spacific putative enhancer RNAs (eRNAs)
  • eRNAs indicate active genetic switches
  • central dogma in Biology: DNA, non-coding RNA, Protein
  • Top 10 Markers
  • Neuropsychiatric Disease: Parkinson: How do genetic variants function in specific brain cells: neurons, microglia, astrocytes
  • genetic variants of neuropsychiatric diseases over-localize to active eRNA sites in dopamine neurons
  • enhancers RNA – ADHD,
  • enhacers RNA – schizoprania, bipolar, addiction – antopsychotic Vlporic acid
  • BRAINCODE Project: BWH MGH HMS

5:00 – 6:00 PM

AWARDS & RECEPTION

SPECIAL PHOTO-OP TO CELEBRATE YOU!
WE WILL TAKE A GROUP PHOTO DURING THE RECEPTION AND AWARDS CEREMONY TO CELEBRATE YOU, OUR INNOVATORS!
THE PHOTO WILL BE DISPLAYED AT THE BRIGHAM IN THE HALE BUILDING. WE HOPE YOU CAN JOIN US IN CELEBRATING YOUR ACHIEVEMENTS.

SOURCE

http://www.discoverbrigham.org/agenda/

Read Full Post »


Real Time Coverage @BIOConvention #BIO2019: Gene Therapy 2.0: No Longer Science Fiction 1:00-2:15 pm June 3 Philadelphia PA

Reporter: Stephen J. Williams Ph.D. @StephenJWillia2

kkjk

Other Articles on Gene Therapy on this Open Access Journal Include:

Read Full Post »


Real Time Coverage @BIOConvention #BIO2019: Precision Medicine Beyond Oncology June 5 Philadelphia PA

Reporter: Stephen J Williams PhD @StephenJWillia2

Precision Medicine has helped transform cancer care from one-size-fits-all chemotherapy to a new era, where patients’ tumors can be analyzed and therapy selected based on their genetic makeup. Until now, however, precision medicine’s impact has been far less in other therapeutic areas, many of which are ripe for transformation. Efforts are underway to bring the successes of precision medicine to neurology, immunology, ophthalmology, and other areas. This move raises key questions of how the lessons learned in oncology can be used to advance precision medicine in other fields, what types of data and tools will be important to personalizing treatment in these areas, and what sorts of partnerships and payer initiatives will be needed to support these approaches and their ultimate commercialization and use. The panel will also provide an in depth look at precision medicine approaches aimed at better understanding and improving patient care in highly complex disease areas like neurology.
Speaker panel:  The big issue now with precision medicine is there is so much data and hard to put experimental design and controls around randomly collected data.
  • The frontier is how to CURATE randomly collected data to make some sense of it
  • One speaker was at a cancer meeting and the oncologist had no idea what to make of genomic reports they were given.  Then there is a lack of action or worse a misdiagnosis.
  • So for e.g. with Artificial Intelligence algorithms to analyze image data you can see things you can’t see with naked eye but if data quality not good the algorithms are useless – if data not curated properly data is wasted
Data needs to be organized and curated. 
If relying of AI for big data analysis the big question still is: what are the rates of false negative and false positives?  Have to make sure so no misdiagnosis.

Please follow LIVE on TWITTER using the following @ handles and # hashtags:

@Handles

@pharma_BI

@AVIVA1950

@BIOConvention

# Hashtags

#BIO2019 (official meeting hashtag)

Read Full Post »


Reporter: Stephen J. Williams, PhD @StephenJWillia2

Science and technology bring tremendous value to society in years of life and quality of life, yet the public often perceives science as difficult, irrelevant or even threatening. Moreover, the inspirational and moving stories of scientists and innovators working around the world are often hidden or misrepresented in popular culture. Whose responsibility is it to communicate science and engage the public in supporting the scientific enterprise? Can everyone be a Champion of Science and what are the solutions to enlist and engage more champions of science across generations and geographies? How do we work together to enhance transparency, accessibility and relevance of science for everyone, everywhere? Can science become more inclusive and engage hearts and not only minds?

Join this exciting session as Johnson & Johnson announces the winners of the Champions of Science – BioGENEius Storytelling Challenge, and brings together other key stakeholders in a discussion about the importance of engaging the public to fall in love in science all over again.

Sponsored by: Johnson & Johnson Innovation

Seema: We need to solve the problem of the lack of trust in scientists.  Some of JNJ winners of their acheivement program went on to become Nobel Laureates.   Arthur Horwich and Hans Ullrich won the Jannsen Award for discovering compounds that could refold proteins, including protein chaperones.  Many diseases occur because of protein misfolding like neuro-degenerative diseases.
Seema:  Great science going on in Africa.  JNJ wanted to showcase the great science in Africa. they awarded four individuals with storytelling award (Emily).
Dr. Horwich: got interested in science early on.  Worked on N terminal mitochondrial signal peptides.  also then got interested in how proteins fold and unfold and refold since the 1950s.  He had changed the thinking of how proteins are processed within cells and over many years he had worked on this.
Emily Wang:  Parents and schoolteachers prodded her curiosity in biology. The impact of day to day work of scientists is arduous but the little things can lead to advances that may help people.  If passionate and have a great mentor then can get a foot in the door.  Worked at Stanford in the lab.
Dr. Mukherjee: He likes to cure diseases, physican first, scientist second, writer third but he doesn’t separate this.  In older times scientists wrote to think and true today. How we visualize the word, or use our hands, is similar.  He takes the word translational research very seriously.  Can you say in one sentence how this will help patients in three years?
There are multitude ways of love for science.
Dr. Pinela: loved asking big question and loved storytelling but asking bigger questions. Moved from Columbia and moved to US; loved the freedom and government funding situation at that time.  Need the training and mentorship so mentors are a very big aspect in innovation as it led her to entrepreneurship.  We need to use technology to disrupt and innovate.
Nsikin:  A lot of mentors nurture curiosity.  People like to see them in that story of curiosity.  That is how is bases the PBS science videos: did  a study on engagement and people wants a morality, and a science identity (an inner nerd in all of us i.e. spark the interest).  The feedback if they focus on this has been positive.

Please follow LIVE on TWITTER using the following @ handles and # hashtags:

@Handles

@pharma_BI

@AVIVA1950

@BIOConvention

# Hashtags

#BIO2019 (official meeting hashtag)

Read Full Post »


Real Time Coverage @BIOConvention #BIO2019: June 4 Morning Sessions; Global Biotech Investment & Public-Private Partnerships

Reporter: Stephen J Williams PhD @StephenJWillia2

Each country have their own needs and most important drug cost structure. Must involve patients and providers.
BCI survey: countries output different, who improved who didnt
Is industry having collaboration with government? hardly ten percent by survey and worse vice versa
Transparancy and holistic view important for collaboration
Korea: lack of communication need input from government on pricing; wants global open innovation and enhance RD investments
Tawain: price, price but based on efficacy; pharma needs to talk with doctors hospital patients, find balance
Pitts: we need trust; staff that country offices with people who know that country. Price not defining value
Columbia:  need to attract investors

Please follow LIVE on TWITTER using the following @ handles and # hashtags:

@Handles

@pharma_BI

@AVIVA1950

@BIOConvention

# Hashtags

#BIO2019 (official meeting hashtag)

Read Full Post »

Older Posts »